Financial Consulate’s Nektar Therapeutics NKTR Stock Holding History

Financial Consulate’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$788	Buy	+13	New	+$913	﹤0.01%	1361

Other funds holding NKTR

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.19B AUM 19.73% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Financial Consulate's NKTR Position: Q3 2026 in Review

Financial Consulate opened a new position in Nektar Therapeutics (NKTR) in Q3 2026: 13 shares worth $788. The stake represents ﹤0.01% of the portfolio and ranks #1361 among its holdings.

20 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

Financial Consulate held 13 shares of Nektar Therapeutics worth $788 as of Q3 2026.
Nektar Therapeutics was a new Financial Consulate position in Q3 2026.
Nektar Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1361 holding.
20 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.